Latest regarding breast implant safety -PRASEAG
Statement from the Chair of the PRASEAG – 4 April 2019
Breast cancer experts from across the UK have been working together to look at the risk to people with breast implants of developing a very rare form of cancer. This follows the news that some types of breast implants have been withdrawn in France.
Based on analysis of the latest scientific evidence and on expert clinical opinion, the Medicines and Healthcare products Regulatory Agency (MHRA) advises that there is no need for people with breast implants in the UK to have them removed because there is no new evidence that the risk has
changed. The situation will be reviewed regularly by the MHRA.
If people are worried following their breast implant surgery, they should see their GP or the surgeon who did the implant. This is particularly important if they notice swelling around their implant more than six months after having the breast implant (regardless of how many years later).
The MHRA issued this advice following close working with the British Association of Plastic, Reconstructive and Aesthetic Surgeons, the Association of Breast Surgery, the British Association of Aesthetic Plastic
Surgeons and other experts to assess the risks associated with breast implant associated anaplastic large cell lymphoma (BIA‐ALCL). MHRA is also working closely with organisations doing similar regulatory work in Europe and internationally.
In addition, the independent Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group (PRASEAG) has been monitoring UK cases of BIA‐ALCL and working closely with MHRA and the information is regularly updated on the MHRA website.
MHRA is continuing to collect evidence and investigate the disease, both nationally and internationally. Clinicians are being informed of the need to report all cases of BIA‐ALCL or suspected
BIA‐ALCL to the MHRA via the Yellow Card scheme.